Shareholders of Yinnuo Pharmaceutical-B (02591) with a total market value of HK$189 million deposited 265.564 million shares into Haitong International Securities

The Zhitong Finance App learned that the latest data from the Hong Kong Stock Exchange shows that on August 13, Yinnuo Pharmaceutical-B (02591) had a position change, with a total market value of HK$189 million, accounting for 6.32%. The company's shareholders deposited 26.5564 million shares into Haitong International Securities, increasing their shareholding ratio by 6.32%.

According to Yinnuo Pharmaceutical's annual results for the year ended December 31, 2025, the Group's revenue was approximately RMB 131.5 million, mainly from sales of esupaglutide α in China. Net loss was RMB 341 million, up 95.4% year on year; basic loss per share was RMB 0.79.